Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leader in wearable cardiac care solutions, is set to showcase its groundbreaking ASSURE® Wearable Cardioverter Defibrillator (WCD) system at the Heart Rhythm 2025 conference, taking place from April 24–27 at the San Diego Convention Center. This event marks Kestra’s first major industry appearance following its successful IPO earlier this year. The company will present an immersive in-booth experience at Booth 1505, highlighting how the ASSURE® system is redefining protection for patients at risk of sudden cardiac arrest (SCA).
The ASSURE® system combines lifesaving defibrillation therapy with intuitive, intelligent and connected diagnostic and patient support capabilities. It features advanced technologies such as the ASSURE Detection Algorithm with Quad Channel Processing™ and Adaptive Patient Intelligence™, designed to provide real-time, personalized cardiac monitoring and intervention.
In addition to the product showcase, Kestra will present new real-world clinical data demonstrating the impact of the ASSURE® system on patient outcomes.
The company is also sponsoring the Women in EP Luncheon for the fourth consecutive year, underscoring its commitment to leadership, innovation, and equity in cardiovascular care.
“Our presence at Heart Rhythm 2025 comes at a pivotal time for Kestra,” said Brian Webster, President and CEO of Kestra. “Following our IPO, we’re moving forward with increasing momentum and this year’s HRS meeting is an opportunity to demonstrate how the ASSURE® system goes beyond protection to offer a smarter, more connected recovery experience for both patients and care teams.”
For more information about the ASSURE® system and Kestra’s participation in Heart Rhythm 2025, visit kestramedical.com.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. For personalized medical guidance, please consult a qualified healthcare professional.
